Latest developments
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A…
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a…
Beckman Coulter, a global leader in clinical diagnostics, and Scopio Labs, a medtech company that develops AI-powered workflow solutions, announced today a worldwide partnership to accelerate adoption of Scopio's next generation…
Subscribe to our mailing list
Get our newsletter, Kreos updates and information on our events right to your mailbox.
Market Leading Growth Debt Investor for +22 years
Kreos Capital provides innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.
For over 22 years, our sole focus has been to support our ambitious ecosystem with personal, adaptable and responsive financing through every stage of the growth life cycle – from entry level through to late-stage growth including pre and post-IPO.
